Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Exelixis, Inc. stock logo
EXEL
Exelixis
$65.91
+0.1%
$63.03
$39.71
▼
$73.69
$16.09B0.452.62 million shs297,349 shs
7 Energy Stocks to Buy and Hold Forever Cover

Oil still powers the global economy, but AI is reshaping the energy opportunity. Discover seven stocks spanning traditional energy, infrastructure, and next-generation power.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Exelixis, Inc. stock logo
EXEL
Exelixis
-3.60%-5.74%+2.24%+21.73%+56.22%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Exelixis, Inc. stock logo
EXEL
Exelixis
$65.91
+0.1%
$63.03
$39.71
▼
$73.69
$16.09B0.452.62 million shs297,349 shs
7 Energy Stocks to Buy and Hold Forever Cover

Oil still powers the global economy, but AI is reshaping the energy opportunity. Discover seven stocks spanning traditional energy, infrastructure, and next-generation power.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Exelixis, Inc. stock logo
EXEL
Exelixis
-3.60%-5.74%+2.24%+21.73%+56.22%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Exelixis, Inc. stock logo
EXEL
Exelixis
2.41
Hold$58.62-11.06% Downside

Current Analyst Ratings Breakdown

Latest EXEL Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
11/13/2026
Exelixis, Inc. stock logo
EXEL
Exelixis
Lower Price TargetEqual Weight$60.00 ➝ $57.00
11/5/2026
Exelixis, Inc. stock logo
EXEL
Exelixis
Boost Price TargetMarket Perform$55.00 ➝ $58.00
11/2/2026
Exelixis, Inc. stock logo
EXEL
Exelixis
Boost Price TargetBuy$56.00 ➝ $78.00
10/30/2026
Exelixis, Inc. stock logo
EXEL
Exelixis
Reiterated RatingMarket Perform$60.00
10/30/2026
Exelixis, Inc. stock logo
EXEL
Exelixis
Boost Price TargetBuy$55.00 ➝ $76.00
10/30/2026
Exelixis, Inc. stock logo
EXEL
Exelixis
Boost Price TargetEqual Weight$53.00 ➝ $60.00
10/30/2026
Exelixis, Inc. stock logo
EXEL
Exelixis
Boost Price TargetHold$54.00 ➝ $60.00
10/30/2026
Exelixis, Inc. stock logo
EXEL
Exelixis
Boost Price TargetSector Perform$51.00 ➝ $58.00
10/30/2026
Exelixis, Inc. stock logo
EXEL
Exelixis
Boost Price TargetEqual Weight$49.00 ➝ $54.00
10/19/2026
Exelixis, Inc. stock logo
EXEL
Exelixis
Reiterated RatingMarket Outperform
(Data available from 11/20/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Exelixis, Inc. stock logo
EXEL
Exelixis
$2.32B6.93$2.92 per share22.56$7.52 per share8.76
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Exelixis, Inc. stock logo
EXEL
Exelixis
$782.57M$3.3419.7517.341.7635.45%45.54%33.90%N/A

Latest EXEL Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
10/29/2026Q3 2026
Exelixis, Inc. stock logo
EXEL
Exelixis
$0.8870$0.94+$0.0530$0.85$646.51 million$658.70 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Exelixis, Inc. stock logo
EXEL
Exelixis
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Exelixis, Inc. stock logo
EXEL
Exelixis
N/A
3.21
3.14

Institutional Ownership

CompanyInstitutional Ownership
Exelixis, Inc. stock logo
EXEL
Exelixis
85.27%

Insider Ownership

CompanyInsider Ownership
Exelixis, Inc. stock logo
EXEL
Exelixis
2.60%
CompanyEmployeesShares OutstandingFree FloatOptionable
Exelixis, Inc. stock logo
EXEL
Exelixis
1,077244.01 million237.67 millionOptionable

Recent News About These Companies

Exelixis (EXEL) Trades 11% Above Fair Value As Pipeline Hopes Build
Exelixis (EXEL) Stock May Be Below Fair Value After Cancer Study Data
Should You Buy Exelixis Stock For Its Cash?
Exelixis Eyes Q1 Zanza Data as It Plans Beyond CABO
Exelixis Eyes Turning Point as Colorectal Cancer Drug Decision Nears
Forget clinical cash burns: Why Exelixis is up 38% since June

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Exelixis stock logo

Exelixis NASDAQ:EXEL

$65.91 +0.08 (+0.12%)
As of 11:59 AM Eastern
This is a fair market value price provided by Massive. Learn more.

Exelixis, Inc., an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, RET, and VEGF receptors. The company also offers COTELLIC, an inhibitor of MEK as a combination regimen to treat specific forms of advanced melanoma; and MINNEBRO, an oral non-steroidal selective blocker of the mineralocorticoid receptor for the treatment of hypertension in Japan. It develops zanzalintinib, a novel, potent, next-generation oral tyrosine kinase inhibitor (TKI) that targets VEGF receptors, MET and the TAM kinases (TYRO3, AXL and MER); and XB002, a next-generation tissue factor (TF)-targeting ADC, administered via intravenous infusion and composed of a human monoclonal antibody (mAb) against TF that is conjugated to an auristatin-based microtubulin inhibitor (MTI) payload. It has research collaborations and license agreements with Ipsen Pharma SAS; Takeda Pharmaceutical Company Ltd.; F. Hoffmann-La Roche Ltd.; Redwood Bioscience, Inc.; R.P. Scherer Technologies, LLC; Catalent Pharma Solutions, Inc.; NBE Therapeutics AG; Aurigene Discovery Technologies Limited; Iconic Therapeutics, Inc.; Invenra, Inc.; StemSynergy Therapeutics, Inc.; Genentech, Inc.; Bristol-Myers Squibb Company; and Daiichi Sankyo Company, Limited, as well as clinical development agreement with Sairopa B.V. for ADU-1805. The company was formerly known as Exelixis Pharmaceuticals, Inc. and changed its name to Exelixis, Inc. in February 2000. Exelixis, Inc. was incorporated in 1994 and is headquartered in Alameda, California.